Advertisement

L-Asparaginase

  • Ines Mader
  • Patrizia E. Fürst-Weger
  • Robert M. Mader
  • Elisabeth I. Semenitz
  • Robert Terkola
  • Sabine M. Wassertheurer

Keywords

Infusion Lead Cancer Chemotherapeutic Agent Oncological Society Drug Monograph Documentation Sheet 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Original articles

  1. [1]
    Oettgen HF, Stephenson PA, Schwartz MK, et al: Toxicity of E. coli Lasparaginase in man. Cancer 25: 253–278, 1970.Google Scholar
  2. [2]
    Haskell CM, Canellos GP, Leventhal BG, et al: L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med 281: 1028–1034, 1969.PubMedCrossRefGoogle Scholar
  3. [3]
    Barr RD, Benton SG, Belbeck LW: Soft-tissue necrosis induced by extravasated cancer chemotherapeutic agents. J Natl Cancer Inst 66: 1129–1136, 1981.PubMedGoogle Scholar

Secondary literature

  1. [4]
    Dorr RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev 4: 41–60, 1990.PubMedCrossRefGoogle Scholar
  2. [5]
    Stanley A: Managing complications of chemotherapy. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 3rd edition: 105–124, 1997.Google Scholar
  3. [6]
    Schneider G: Paravasate von Zytostatika. Diagnostik und Therapie. Aina S Schneider Verlag, 6th edition: 1–17, 1999.Google Scholar
  4. [7]
    Schneider SM, Distelhorst CW: Chemotherapy-induced emergencies. Semin Oncol 16: 572–578, 1989.PubMedGoogle Scholar
  5. [8]
    Ignoffo RJ, Friedman MA: Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17–27, 1980.PubMedCrossRefGoogle Scholar
  6. [9]
    Dorr RT: Pharmacologic management of vesicant chemotherapy extravasations. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton and Lange, 2nd edition: 109–118, 1994.Google Scholar
  7. [10]
    Cox K, Stuart-Harris R, Abdini G, et al: The management of cytotoxicdrug extravasation: guide-lines drawn up by a working party for the Clinical Oncological Society of Australia. Med J Aust 148: 185–189, 1988.PubMedGoogle Scholar
  8. [11]
    Fuxius S, Unger C: Pegaspargase. Arzneimitteltherapie 16: 170–173, 1998.Google Scholar
  9. [12]
    Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 1, 2nd edition: A42–44, 1997.Google Scholar
  10. [13]
    Dorr RT, Von Hoff DD: Drug monographs: asparaginase. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton and Lange, 2nd edition: 201–209, 1994.Google Scholar
  11. [14]
    Summary of product characteristics Asparaginase medac (Germany), Medac, September 1995.Google Scholar

Copyright information

© Springer-Verlag Wien 2003

Authors and Affiliations

  • Ines Mader
    • 1
  • Patrizia E. Fürst-Weger
    • 2
  • Robert M. Mader
    • 3
  • Elisabeth I. Semenitz
    • 4
  • Robert Terkola
    • 5
  • Sabine M. Wassertheurer
    • 6
  1. 1.Austrian Breast and Colorectal Cancer Study GroupViennaAustria
  2. 2.SMZ FloridsdorfKrankenhaus und GeriatriezentrumViennaAustria
  3. 3.Clinical Division of Oncology, Department of Medicine IUniversity HospitalViennaAustria
  4. 4.AnstaltsapothekeLandeskrankenhaus — Universitätskliniken InnsbruckAustria
  5. 5.Kaiser-Franz-Josef HospitalViennaAustria
  6. 6.Apotheke LKH-Univ.-Klinikum GrazAustria

Personalised recommendations